Login to Your Account

Dyax Inks Potential $855M Discovery Deal with Biogen Idec

By Trista Morrison

Friday, February 6, 2009
A day after an FDA advisory panel narrowly backed the approval of Dyax Corp.'s Kalbitor (ecallantide, DX-88) for acute attacks of hereditary angioedema, the company expanded its phage display drug discovery deal with Biogen Idec Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription